Achievements & Awards


Majlis Menandatangani MOU di antara PPUM dan Novo Nordisk Pharma (M) Sdn. Bhd.

Pusat Penyelidikan Klinikal atau lebih dikenali sebagai Clinical Investigation Centre (CIC), adalah sebuah pusat penyelidikan klinikal yang bertempat di Pusat Perubatan Universiti Malaya (PPUM) telah mencipta sejarah baru apabila dipilih sebagai Strategic Site Pertama di Asia Tenggara oleh Novo Nordisk Pharma (M) Sdn. Bhd.

Satu Memorandum Persefahaman telah ditandatangani pada 26 November 2019 oleh YM Prof. Dr. Tunku Kamarul Zaman Tunku Zainol Abidin, selaku Pengarah Pusat Perubatan Universiti Malaya (PPUM), dengan En. Richard Abela, Timbalan Presiden dan Pengurus Am Novo Nordisk. Pemilihan CIC PPUM sebagai Strategic site Pertama berdasarkan reputasi, pencapaian dan kemampuan CIC PPUM yang berdaya saing dalam menjalankan ujian percubaan klinikal di peringkat global.

Pada tahun 2010, CIC PPUM telah dinobatkan oleh, yang kini dikenali sebagai IQVIA, (CRO bagi penyelidikan klinikal daripada Amerika Syarikat) sebagai Prime Site yang pertama di Asia untuk pengendalian penyelidikan klinikal.

Pada tahun 2013, Pfizer.Inc (Syarikat farmaseutikal daripada Amerika Syarikat) telah memilih CIC PPUM sebagai Investigator Networks, Site Partnerships and Infrastructure for Research Excellence (INSPIRE) Site yang pertama. Parexel International (CRO bagi penyelidikan klinikal daripada Amerika Syarikat), salah satu daripada CRO yang terbaik di dunia, telah memilih CIC PPUM sebagai Alliance Site yang pertama di Malaysia pada tahun 2016. Pada tahun 2019, CIC PPUM juga telah memeterai Memorandum Persefahaman bersama dengan Novotech Malaysia pada bulan Februari 2019 dan seterusnya dengan pihak Prima Nexus Sdn. Bhd. pada bulan April 2019.

CIC PPUM telah memenangi lebih daripada 21 anugerah dan pengiktirafan terbaik sejak tahun 2013 dalam negara, tempat ke-3 dalam APAC dan tempat ke-7 di peringkat global bagi IQVIA Prime Sites pada tahun 2017. Seterusnya, tempat pertama sebagai IQVIA Malaysia Prime Sites pada tahun 2017. CIC PPUM juga telah mengumumkan pencapaian mereka yang terbaru iaitu perekrutan pesakit pertama di dunia (First Patient in the World) untuk tiga (3) penyelidikan klinikal dan pesakit pertama di Malaysia (First Patient in Malaysia) untuk sebelas (11) penyelidikan klinikal yang dikendalikan di PPUM. Ini menunjukkan CIC PPUM terus cemerlang dalam mengharumkan nama PPUM dan Malaysia di persada dunia.

Sejak penubuhannya, CIC PPUM telah menjalankan lebih daripada 622 penyelidikan klinikal dan kini sedang bekerjasama dengan lebih 300 penyelidik termasuk Ketua Penyelidik, Penyelidik Bersama dan Pembantu Penyelidik bagi mengendalikan 194 penyelidikan klinikal yang masih aktif di CIC PPUM.

Novo Nordisk merupakan syarikat perkhidmatan kesihatan bertaraf global, yang beribu pejabat di Denmark mempunyai banyak pengalaman, berinovasi dan berkepimpinan lebih 95 tahun dalam penjagaan diabetes. Legasi ini telah memberikan lebih pengalaman dan kemampuan kepada Novo Nordisk bagi membolehkan mereka membantu pesakit mendapatkan rawatan penyakit kronik seperti haemophilia, gangguan pertumbuhan dan obesiti.

Kolaborasi ini akan menjadi satu landasan bagi mencapai perkembangan dan piawaian ubat-ubatan yang baru dan lebih berkesan dengan adanya rekrutmen subjek yang efisen serta penyelidikan klinikal yang berkualiti tinggi. Dengan ini, kedua-dua pihak dapat berkongsi ilmu dalam penyelidikan klinikal dan seterusnya dapat mencapai visi negara untuk menjadikan Malaysia sebagai destinasi pilihan bagi industry-sponsored research oleh syarikat-syarikat Farmaseutikal dari seluruh dunia.

PPUM sangat berbesar hati dengan penyaksian pemeteraian MoU ini dan yakin usahasama di antara dua pihak ini akan terus memacu kemajuan dalam pengkajian ubat-ubatan bertaraf dunia.

 

Signing Memorandum of Understanding UMMC and Novo Nordisk Pharma (M) Sdn. Bhd. Clinical Investigation Centre (CIC) or known as Pusat Penyelidikan Klinikal, a clinical trial centre based in University Malaya Medical Centre (UMMC) has invented a new history after been selected as the First Strategic site in Asia by Novo Nordisk Pharma (M) Sdn. Bhd.

A Memorandum of Understanding (MoU) was signed on 26 November 2019 by YM. Prof. Dr Tunku Kamarul Zaman Tunku Zainol Abidin, acting as the Director of University Malaya Medical Centre (UMMC) with Mr Richard Abela, the Vice President and General Manager of Novo Nordisk. The selection of CIC UMMC as the First Strategic site is based on the reputation, achievement and capability of CIC UMMC to be competitive at the international level to conduct a clinical trial.

In 2010, CIC UMMC was recognized by Quintiles, now known as IQVIA (a clinical trial CRO from the United States) as the first Prime Site in Asia for the conduct of clinical trials. In 2013, Pfizer. Inc (a pharmaceutical company from the United States) has selected CIC UMMC as the first site for the Investigator Networks, Site Partnerships and Infrastructure for Research Excellence (INSPIRE) Program. Parexel International (clinical trial CRO from the United States), one of the top CRO in the world has selected CIC UMMC as their first Alliance Site in Malaysia in 2016. In 2019, CIC UMMC has signed MoU with Novotech Malaysia on February 2019 and subsequently with Prima Nexus Sdn. Bhd. in April 2019.

CIC UMMC has won more than 21 accolades and recognitions since 2013 and is recognized as the Top in the country, 3rd in APAC and 7th globally for IQVIA Prime Site ranking in 2017. Subsequently, the first place as IQVIA Malaysia Prime Sites in 2017. CIC also has announced their latest accomplishment in the recruitment of the ‘First Patient in the World’ for three (3) studies and ‘First Patient in Malaysia’ for eleven (11) CIC studies conducted in UMMC. CIC UMMC has reached the standard of excellence and capable of bringing Malaysia name in the eyes of the world.

Since its inception, CIC UMMC has conducted more than 622 clinical trials, and currently working with more than 300 investigators including Principal Investigator, Sub-Investigator and Study Coordinator for 194 active trials in CIC UMMC.

Novo Nordisk is a global healthcare company, headquartered in Denmark with more than 95 years of experience, innovation and leadership in diabetes care. This heritage has given them experience and capabilities that also enable them to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity.

This collaboration will serve as a platform to facilitate the acceleration of the development and standard of new and more effective medicines with efficient subject recruitment and conducting trials with the highest quality. Therefore, both parties can also share their know-how in clinical research and ultimately helps in achieving our country’s vision of establishing Malaysia as a preferred destination for industry-sponsored trial by pharmaceutical companies around the world.

UMMC is delighted to witness this important endeavour and is confident this partnership will drive a new wave of world-class drug development in Malaysia.

 









THIRD PRIZE WINNER FOR BEST TEAM PUBLIC SECTOR (FEDERAL) CATEGORY AT ANNUAL PRODUCTIVITY & INNOVATION CONFERENCE AND EXPOSITION (APIC) 2019

I am pleased to announce that the Quality Improvement Team (QIT) known as CTwarriors from the Department of Biomedical Imaging has won the Third Prize among the 20 Best Public Sector (Federal) category in the Annual Productivity & Innovation Conference and Exposition (APIC) 2019, which was held from 5-7 November 2019 at the Sunway Pyramid Convention Center.

The quality improvement project titled “CT Chest Abdomen Pelvis: Optimizing Contrast Media Based on Body Weight and Bolus Tracking Method” has also received a 5 Star (Gold Award) at the national convention for cost savings and ensuring patient safety. With this award, the CTwarriors team will compete internationally at Dhaka, Bangladesh in 2020.

The APIC 2019 event is an annual program organized by the Malaysian Productivity Corporation (MPC) aimed at providing a platform for various industries to share best practices in improving productivity, quality, innovation, service delivery and customer satisfaction. This year's program was attended by 300 groups representing 125 organizations sharing their effectiveness on productivity improvement projects at their respective organizations.

It is hoped that this success will inspire all the staff of UMMC to pursue quality improvement activities continuously at their respective departments or units

Congratulations to CTwarriors team on their success and achievement! All the best in competing at international platform in 2020.

Thank you.

 










Signing of Memorandum of Understanding (MOU) between University Malaya Medical Center and National Cancer Society of Malaysia

University of Malaya and the National Cancer Society of Malaysia have signed a memorandum of understanding to improve services and research on cancer. In addition, within two years, the main focus is in collaboration with Union For International Cancer Control (UICC) for the City Cancer Challenge 2015 program: Greater Petaling Jaya. The main objective is to increase equity and sustainable access to cancer care in cities such as Petaling Jaya. The agreement was signed by YBhg. Datuk Ir (Dr) Abdul Rahim Hashim, Vice Chancellor UM and Dr. Saunthari Somasundaram, President, National Cancer Society of Malaysia on May 9, 2019 at the University Malaya Medical Center.

 








Signing of Memorandum of Understanding (MOU) between University Malaya Medical Center and Renji Hospital

On April 17, 2019, UMMC and Renji Hospital which joined the Shanghai Jiao Tong University School of Medicine have signed a Memorandum of Understanding for clinical placements to train medical specialists and clinical support staff of UMMC to initiate liver transplant services, especially pediatric patients at PPUM. On behalf of UMMC, the agreement was signed by YM Prof. Tunku Kamarul bin Tunku Zainal Abidin, Director of UMMC while Renji Hospital by Prof.Li Weiping, President of Renji Hospital. Hopefully this clinical placement will increase UMMC’s expertise in surgical services for pediatric patients with liver problems (hepatobiary) and should not be referred overseas.

 






Congratulatory Message on Gold Award and The Best Young Team Excellence Award at Mini Convention Team Excellence (MTEx) 2019 Central Region

Congratulations to the Quality Improvement Project Team (QIT) from the Department of Biomedical Imaging, UMMC for winning the Gold Award and the Best Young Team Excellence Award at the Mini Team Excellence Convention (MTEx) 2019 - Central Region, organised by the Malaysia Productivity Corporation (MPC) on April 18, 2019.

The team, known as CTwarriors, has presented a quality project titled "CT Chest Abdomen Pelvis (CAP): Optimizing Contrast Media Based on Body Weight and Bolus Tracking Method".

The Mini Team Excellence Convention is a platform that provides Quality Improvement team from government and private agencies to present their improvement projects that have produced positive impact towards the organisation and enhance the organisation's image to a higher level.

With this award, the CTwarriors Team will participate at the Regional Team Excellence Convention (RTEx) scheduled in July 2019.

Well done and congratulations again to the CTwarriors team from the Department of Biomedical Imaging for their achievements!

 








Memorandum of Understanding (MOU) Signing Ceremony Between UMMC and Novotech (Malaysia)

On 25 February 2019, UMMC and Novotech (Malaysia) signed a Memorandum of Understanding to increase the number of clinical researches and strengthen the relationship to continue cooperation for all phases (Phase 1 -IV) of the research.

This research is in collaboration with the Clinical Research Department (CIC) as Site Management Organization (SMO) providing high-tech facilities that are regulated internationally, have highly experienced clinical practitioners in the therapeutic field to conduct high quality clinical trials and protect the rights and welfare.






Baby Friendly Hospital

UMMC recognised again as Baby Friendly Hospital Iniatiative Effective From 24 July 2018 until 23 July 2021






Launching of NEWS

Launching of NATIONAL Early Warning Score (NEWS) System and Patient Safety Programme in University Malaya Medical Centre, 22 December 2017

MOU Department of Medical Health, Thailand

Memorandum of Understanding Signing Ceremony First Percutaneous Pulmonary Valve Implantation in Malaysia between University Malaya Medical Centre and Department of Medical Health, Thailand, 18 Ogos 2017

MOU With Lerdsin Hospital, Thailand, 18 May 2017

Charges Information Memorandum of Understanding Signing Ceremony University Malaya Medical Centre With Lerdsin Hospital, Thailand, 18 May 2017

ADDRESS

  • Pusat Perubatan Universiti Malaya,
    Lembah Pantai, 59100,
    Kuala Lumpur, MALAYSIA

EMAIL

  • Email : ummc@ummc.edu.my

TEL

  • Phone No : 03-79494422
    Fax : 03-79492030

WEBSITE

  • WEBSITE : www.ummc.edu.my